Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
Phase 2
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Latanoprost+Dorzolmamide
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT04448223
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT04431687
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet
Phase 3
- Conditions
- HypertensionDyslipidemias
- Interventions
- Drug: CKD-828(placebo)Drug: D326Drug: D326(placebo)Drug: D337(placebo)Drug: D013(placebo)Drug: D013
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 120
- Registration Number
- NCT04388215
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Compare the Pharmacokinetics and Safety of CKD-391
Phase 1
Completed
- Conditions
- Hyperlipidemias
- Interventions
- Drug: CKD-391 10/10mgDrug: D090, D337
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 44
- Registration Number
- NCT04354987
- Locations
- 🇰🇷
Jae-Yong Chung, Gyeonggi-do, Seongnam-si, Korea, Republic of
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT04334213
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389
Phase 1
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Reference drugDrug: Test drug
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 34
- Registration Number
- NCT04322032
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
Phase 3
Completed
- Conditions
- Dyslipidemia Patients With Hypertension
- Interventions
- Drug: D013, D326, D337Drug: placebo of D013, D326, D337Drug: D013, placebo of D326, placebo of D337
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT04312698
- Locations
- 🇰🇷
Yonsei University Medical Center Severance Hospital, Seoul, Korea, Republic of
Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337Drug: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,Drug: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 15
- Registration Number
- NCT04304547
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 15
- Registration Number
- NCT04272502
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1TDrug: CKD-393 0.5/100/1000mg formulation 1 Tab. 1TDrug: CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT04260438
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath